These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 24583061)

  • 61. Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients.
    Liu PH; Hsu CY; Hsia CY; Lee YH; Huang YH; Su CW; Lee FY; Lin HC; Huo TI
    Eur J Cancer; 2016 Aug; 63():25-33. PubMed ID: 27259100
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment of hepatocellular carcinoma in a tertiary Romanian center. Deviations from BCLC recommendations and influence on survival rate.
    Radu P; Groza I; Iancu C; Al Hajjar N; Andreica V; Sparchez Z
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):291-7. PubMed ID: 24078986
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.
    Zhong JH; Xiang BD; Gong WF; Ke Y; Mo QG; Ma L; Liu X; Li LQ
    PLoS One; 2013; 8(7):e68193. PubMed ID: 23874536
    [TBL] [Abstract][Full Text] [Related]  

  • 64. External validation of a simplified BCLC staging system for early hepatocellular carcinoma.
    Santambrogio R; Salceda J; Costa M; Kluger MD; Barabino M; Laurent A; Opocher E; Azoulay D; Cherqui D
    Eur J Surg Oncol; 2013 Aug; 39(8):850-7. PubMed ID: 23726257
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.
    Ciria R; López-Cillero P; Gallardo AB; Cabrera J; Pleguezuelo M; Ayllón MD; Luque A; Zurera L; Espejo JJ; Rodríguez-Perálvarez M; Montero JL; de la Mata M; Briceño J
    Eur J Surg Oncol; 2015 Sep; 41(9):1153-61. PubMed ID: 26118317
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification.
    Kamiyama T; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamachi H; Yamashita K; Shimamura T; Taketomi A
    World J Surg Oncol; 2017 Aug; 15(1):156. PubMed ID: 28830473
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Nomogram of the Barcelona Clinic Liver Cancer system for individual prognostic prediction in hepatocellular carcinoma.
    Hsu CY; Liu PH; Hsia CY; Lee YH; Al Juboori A; Lee RC; Lin HC; Huo TI
    Liver Int; 2016 Oct; 36(10):1498-506. PubMed ID: 26972815
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.
    Weinmann A; Koch S; Niederle IM; Schulze-Bergkamen H; König J; Hoppe-Lotichius M; Hansen T; Pitton MB; Düber C; Otto G; Schuchmann M; Galle PR; Wörns MA
    J Clin Gastroenterol; 2014 Mar; 48(3):279-89. PubMed ID: 24045276
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Selection criteria for hepatic resection in intermediate-stage (BCLC stage B) multiple hepatocellular carcinoma.
    Wada H; Eguchi H; Noda T; Ogawa H; Yamada D; Tomimaru Y; Tomokuni A; Asaoka T; Kawamoto K; Gotoh K; Marubashi S; Umeshita K; Nagano H; Doki Y; Mori M
    Surgery; 2016 Nov; 160(5):1227-1235. PubMed ID: 27395761
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Surgical and oncological outcomes of hepatic resection for BCLC-B hepatocellular carcinoma: a retrospective multicenter analysis among 474 consecutive cases.
    Di Sandro S; Centonze L; Pinotti E; Lauterio A; De Carlis R; Romano F; Gianotti L; De Carlis L;
    Updates Surg; 2019 Jun; 71(2):285-293. PubMed ID: 30941704
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging.
    Yegin EG; Siykhymbayev A; Eren F; Bekiroglu N; Ozdogan OC
    Ann Hepatol; 2013; 12(6):915-25. PubMed ID: 24114822
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combined hepatectomy and radiofrequency ablation versus TACE in improving survival of patients with unresectable BCLC stage B HCC.
    Hou YF; Wei YG; Yang JY; Wen TF; Xu MQ; Yan LN; Li B
    Hepatobiliary Pancreat Dis Int; 2016 Aug; 15(4):378-85. PubMed ID: 27498577
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma.
    Kloeckner R; Pitton MB; Dueber C; Schmidtmann I; Galle PR; Koch S; Wörns MA; Weinmann A
    J Vasc Interv Radiol; 2017 Jan; 28(1):94-102. PubMed ID: 27562621
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Staging systems of hepatocellular carcinoma: A review.
    Tellapuri S; Sutphin PD; Beg MS; Singal AG; Kalva SP
    Indian J Gastroenterol; 2018 Nov; 37(6):481-491. PubMed ID: 30593649
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma.
    Kim JY; Sinn DH; Gwak GY; Choi GS; Saleh AM; Joh JW; Cho SK; Shin SW; Carriere KC; Ahn JH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Clin Mol Hepatol; 2016 Jun; 22(2):250-8. PubMed ID: 27377909
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
    World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Hansmann J; Evers MJ; Bui JT; Lokken RP; Lipnik AJ; Gaba RC; Ray CE
    J Vasc Interv Radiol; 2017 Sep; 28(9):1224-1231.e2. PubMed ID: 28688815
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C.
    Kim YJ; Jung J; Joo JH; Kim SY; Kim JH; Lim YS; Lee HC; Kim JH; Yoon SM
    Radiother Oncol; 2019 Dec; 141():95-100. PubMed ID: 31506181
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database.
    Zhang N; Gu J; Yin L; Wu J; Du MY; Ding K; Huang T; He X
    Oncotarget; 2016 Dec; 7(49):81389-81401. PubMed ID: 27835609
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
    Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
    World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.